Loading…
Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro
Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization. Apatinib is a vascular endothelial growth factor receptor 2 inhibitor independently developed in Chin...
Saved in:
| Published in: | Zhongguo fei ai za zhi 2020-04, Vol.23 (4), p.216-222 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | Chinese |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 222 |
| container_issue | 4 |
| container_start_page | 216 |
| container_title | Zhongguo fei ai za zhi |
| container_volume | 23 |
| creator | Liu, Chao Zhang, Hongbing Li, Yongwen Zhang, Zihe Shi, Ruifeng Xu, Songlin Zhu, Guangsheng Wang, Pan Liu, Hongyu Chen, Jun |
| description | Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization. Apatinib is a vascular endothelial growth factor receptor 2 inhibitor independently developed in China, which has a significant inhibition in a variety of solid tumors. The purpose of this study is to investigate the effects of Apatinib alone or Apatinib combined with mammalian target of rapamycin (mTOR) inhibitor, CCI-779, on small cell lung cancer cell line NCI-H446 in vitro.
The small cell lung cancer cell line NCI-H446 was grew in vitro. The effects of Apatinib alone or Apatinib combined with CCI-779 on proliferation, apoptosis, cell cycle and migration of NCI-H446 small cell lung cancer cells were detected by CCK8; FACS and transwell assays were also carried out; Western blot assays were used to detect vascular endothelial growth factor and cell cycle related protein expression.
CCK8 assays showed that high c |
| doi_str_mv | 10.3779/j.issn.1009-3419.2020.104.08 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a6b6a78ae0b54add8227c9dfc5e81bc7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a6b6a78ae0b54add8227c9dfc5e81bc7</doaj_id><sourcerecordid>2399221974</sourcerecordid><originalsourceid>FETCH-LOGICAL-d220t-30521a037048e3f7837d4432a8e63781b26463e31d2c20f9660af78ca44e8e583</originalsourceid><addsrcrecordid>eNo9kElPwzAQhS0EYv8LyBJcE7zVyxFFQCuVRWK5RpPYaV2ldnFSIf49FhQuYz_7zfdGg9AVJSVXylyvSj8MoaSEmIILakpGGMlSlETvoWNqjCkk1Wo_3_88R-hkGFaESGa4OERHnDFiqNbH6OtmA6MPvsFVXDc-OIs__bjEVTUrchqehaVv_Djgcenwc4q971zKHTFgCBY_-MVOxQ6_rKHvceVymW_DAlcQWpfwY0ZNhZA_P0Mm4nc_pniGDjroB3e-O0_R293tazUt5k_3s-pmXtg85FhwMmEUCFdEaMc7pbmyQnAG2kmuNG2YFJI7Ti1rGemMlASyqwUhnHYTzU_R7JdrI6zqTfJrSF91BF__PMS0qCGNvu1dDbKRoDQ40kwEWKsZU62xXTtxOahVmXX5y9qk-LF1w1iv4jaFPH7NuDGMUaNEdl3sXNtm7ex_5t_W-TcESIPO</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399221974</pqid></control><display><type>article</type><title>Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Liu, Chao ; Zhang, Hongbing ; Li, Yongwen ; Zhang, Zihe ; Shi, Ruifeng ; Xu, Songlin ; Zhu, Guangsheng ; Wang, Pan ; Liu, Hongyu ; Chen, Jun</creator><creatorcontrib>Liu, Chao ; Zhang, Hongbing ; Li, Yongwen ; Zhang, Zihe ; Shi, Ruifeng ; Xu, Songlin ; Zhu, Guangsheng ; Wang, Pan ; Liu, Hongyu ; Chen, Jun</creatorcontrib><description>Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization. Apatinib is a vascular endothelial growth factor receptor 2 inhibitor independently developed in China, which has a significant inhibition in a variety of solid tumors. The purpose of this study is to investigate the effects of Apatinib alone or Apatinib combined with mammalian target of rapamycin (mTOR) inhibitor, CCI-779, on small cell lung cancer cell line NCI-H446 in vitro.
The small cell lung cancer cell line NCI-H446 was grew in vitro. The effects of Apatinib alone or Apatinib combined with CCI-779 on proliferation, apoptosis, cell cycle and migration of NCI-H446 small cell lung cancer cells were detected by CCK8; FACS and transwell assays were also carried out; Western blot assays were used to detect vascular endothelial growth factor and cell cycle related protein expression.
CCK8 assays showed that high c</description><identifier>ISSN: 1009-3419</identifier><identifier>EISSN: 1999-6187</identifier><identifier>DOI: 10.3779/j.issn.1009-3419.2020.104.08</identifier><identifier>PMID: 32209188</identifier><language>chi</language><publisher>China: Chinese Anti-Cancer Association Chinese Antituberculosis Association</publisher><subject>Antineoplastic Agents - pharmacology ; apatinib ; Apoptosis ; Apoptosis - drug effects ; Breast cancer ; cci-779 ; Cell cycle ; Cell Line, Tumor ; cell migration ; Cell Movement - drug effects ; Cell Proliferation - drug effects ; Dose-Response Relationship, Drug ; Drug Interactions ; Humans ; Lung cancer ; lung neoplasms ; Lung Neoplasms - pathology ; Metastasis ; mtor inhibitor ; Pyridines - pharmacology ; Sirolimus - analogs & derivatives ; Sirolimus - pharmacology ; Small Cell Lung Carcinoma - pathology ; Vascular endothelial growth factor</subject><ispartof>Zhongguo fei ai za zhi, 2020-04, Vol.23 (4), p.216-222</ispartof><rights>Copyright © 2020. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2399221974/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2399221974?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25731,27901,27902,36989,44566,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32209188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Chao</creatorcontrib><creatorcontrib>Zhang, Hongbing</creatorcontrib><creatorcontrib>Li, Yongwen</creatorcontrib><creatorcontrib>Zhang, Zihe</creatorcontrib><creatorcontrib>Shi, Ruifeng</creatorcontrib><creatorcontrib>Xu, Songlin</creatorcontrib><creatorcontrib>Zhu, Guangsheng</creatorcontrib><creatorcontrib>Wang, Pan</creatorcontrib><creatorcontrib>Liu, Hongyu</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><title>Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro</title><title>Zhongguo fei ai za zhi</title><addtitle>Zhongguo Fei Ai Za Zhi</addtitle><description>Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization. Apatinib is a vascular endothelial growth factor receptor 2 inhibitor independently developed in China, which has a significant inhibition in a variety of solid tumors. The purpose of this study is to investigate the effects of Apatinib alone or Apatinib combined with mammalian target of rapamycin (mTOR) inhibitor, CCI-779, on small cell lung cancer cell line NCI-H446 in vitro.
The small cell lung cancer cell line NCI-H446 was grew in vitro. The effects of Apatinib alone or Apatinib combined with CCI-779 on proliferation, apoptosis, cell cycle and migration of NCI-H446 small cell lung cancer cells were detected by CCK8; FACS and transwell assays were also carried out; Western blot assays were used to detect vascular endothelial growth factor and cell cycle related protein expression.
CCK8 assays showed that high c</description><subject>Antineoplastic Agents - pharmacology</subject><subject>apatinib</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Breast cancer</subject><subject>cci-779</subject><subject>Cell cycle</subject><subject>Cell Line, Tumor</subject><subject>cell migration</subject><subject>Cell Movement - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Interactions</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>lung neoplasms</subject><subject>Lung Neoplasms - pathology</subject><subject>Metastasis</subject><subject>mtor inhibitor</subject><subject>Pyridines - pharmacology</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sirolimus - pharmacology</subject><subject>Small Cell Lung Carcinoma - pathology</subject><subject>Vascular endothelial growth factor</subject><issn>1009-3419</issn><issn>1999-6187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNo9kElPwzAQhS0EYv8LyBJcE7zVyxFFQCuVRWK5RpPYaV2ldnFSIf49FhQuYz_7zfdGg9AVJSVXylyvSj8MoaSEmIILakpGGMlSlETvoWNqjCkk1Wo_3_88R-hkGFaESGa4OERHnDFiqNbH6OtmA6MPvsFVXDc-OIs__bjEVTUrchqehaVv_Djgcenwc4q971zKHTFgCBY_-MVOxQ6_rKHvceVymW_DAlcQWpfwY0ZNhZA_P0Mm4nc_pniGDjroB3e-O0_R293tazUt5k_3s-pmXtg85FhwMmEUCFdEaMc7pbmyQnAG2kmuNG2YFJI7Ti1rGemMlASyqwUhnHYTzU_R7JdrI6zqTfJrSF91BF__PMS0qCGNvu1dDbKRoDQ40kwEWKsZU62xXTtxOahVmXX5y9qk-LF1w1iv4jaFPH7NuDGMUaNEdl3sXNtm7ex_5t_W-TcESIPO</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Liu, Chao</creator><creator>Zhang, Hongbing</creator><creator>Li, Yongwen</creator><creator>Zhang, Zihe</creator><creator>Shi, Ruifeng</creator><creator>Xu, Songlin</creator><creator>Zhu, Guangsheng</creator><creator>Wang, Pan</creator><creator>Liu, Hongyu</creator><creator>Chen, Jun</creator><general>Chinese Anti-Cancer Association Chinese Antituberculosis Association</general><general>Chinese Anti-Cancer Association; Chinese Antituberculosis Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BVBZV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20200401</creationdate><title>Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro</title><author>Liu, Chao ; Zhang, Hongbing ; Li, Yongwen ; Zhang, Zihe ; Shi, Ruifeng ; Xu, Songlin ; Zhu, Guangsheng ; Wang, Pan ; Liu, Hongyu ; Chen, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d220t-30521a037048e3f7837d4432a8e63781b26463e31d2c20f9660af78ca44e8e583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2020</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>apatinib</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Breast cancer</topic><topic>cci-779</topic><topic>Cell cycle</topic><topic>Cell Line, Tumor</topic><topic>cell migration</topic><topic>Cell Movement - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Interactions</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>lung neoplasms</topic><topic>Lung Neoplasms - pathology</topic><topic>Metastasis</topic><topic>mtor inhibitor</topic><topic>Pyridines - pharmacology</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sirolimus - pharmacology</topic><topic>Small Cell Lung Carcinoma - pathology</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Chao</creatorcontrib><creatorcontrib>Zhang, Hongbing</creatorcontrib><creatorcontrib>Li, Yongwen</creatorcontrib><creatorcontrib>Zhang, Zihe</creatorcontrib><creatorcontrib>Shi, Ruifeng</creatorcontrib><creatorcontrib>Xu, Songlin</creatorcontrib><creatorcontrib>Zhu, Guangsheng</creatorcontrib><creatorcontrib>Wang, Pan</creatorcontrib><creatorcontrib>Liu, Hongyu</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>East & South Asia Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Directory of Open Access Journals</collection><jtitle>Zhongguo fei ai za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Chao</au><au>Zhang, Hongbing</au><au>Li, Yongwen</au><au>Zhang, Zihe</au><au>Shi, Ruifeng</au><au>Xu, Songlin</au><au>Zhu, Guangsheng</au><au>Wang, Pan</au><au>Liu, Hongyu</au><au>Chen, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro</atitle><jtitle>Zhongguo fei ai za zhi</jtitle><addtitle>Zhongguo Fei Ai Za Zhi</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>23</volume><issue>4</issue><spage>216</spage><epage>222</epage><pages>216-222</pages><issn>1009-3419</issn><eissn>1999-6187</eissn><abstract>Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization. Apatinib is a vascular endothelial growth factor receptor 2 inhibitor independently developed in China, which has a significant inhibition in a variety of solid tumors. The purpose of this study is to investigate the effects of Apatinib alone or Apatinib combined with mammalian target of rapamycin (mTOR) inhibitor, CCI-779, on small cell lung cancer cell line NCI-H446 in vitro.
The small cell lung cancer cell line NCI-H446 was grew in vitro. The effects of Apatinib alone or Apatinib combined with CCI-779 on proliferation, apoptosis, cell cycle and migration of NCI-H446 small cell lung cancer cells were detected by CCK8; FACS and transwell assays were also carried out; Western blot assays were used to detect vascular endothelial growth factor and cell cycle related protein expression.
CCK8 assays showed that high c</abstract><cop>China</cop><pub>Chinese Anti-Cancer Association Chinese Antituberculosis Association</pub><pmid>32209188</pmid><doi>10.3779/j.issn.1009-3419.2020.104.08</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1009-3419 |
| ispartof | Zhongguo fei ai za zhi, 2020-04, Vol.23 (4), p.216-222 |
| issn | 1009-3419 1999-6187 |
| language | chi |
| recordid | cdi_doaj_primary_oai_doaj_org_article_a6b6a78ae0b54add8227c9dfc5e81bc7 |
| source | Open Access: PubMed Central; Publicly Available Content Database |
| subjects | Antineoplastic Agents - pharmacology apatinib Apoptosis Apoptosis - drug effects Breast cancer cci-779 Cell cycle Cell Line, Tumor cell migration Cell Movement - drug effects Cell Proliferation - drug effects Dose-Response Relationship, Drug Drug Interactions Humans Lung cancer lung neoplasms Lung Neoplasms - pathology Metastasis mtor inhibitor Pyridines - pharmacology Sirolimus - analogs & derivatives Sirolimus - pharmacology Small Cell Lung Carcinoma - pathology Vascular endothelial growth factor |
| title | Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A56%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apatinib%20Combined%20with%20CCI-779%20Inhibits%20the%20Proliferation%20and%20Migration%20of%20Small%20Cell%20Lung%20Cancer%20NCI-H446%20Cells%20In%20Vitro&rft.jtitle=Zhongguo%20fei%20ai%20za%20zhi&rft.au=Liu,%20Chao&rft.date=2020-04-01&rft.volume=23&rft.issue=4&rft.spage=216&rft.epage=222&rft.pages=216-222&rft.issn=1009-3419&rft.eissn=1999-6187&rft_id=info:doi/10.3779/j.issn.1009-3419.2020.104.08&rft_dat=%3Cproquest_doaj_%3E2399221974%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d220t-30521a037048e3f7837d4432a8e63781b26463e31d2c20f9660af78ca44e8e583%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2399221974&rft_id=info:pmid/32209188&rfr_iscdi=true |